Financial Overview - The total assets of the company at the end of the reporting period amounted to CNY 2,320,746,040.93, an increase from CNY 2,290,524,143.62 at the beginning of the period, reflecting a growth of approximately 1.32% [1][2][3] - Total liabilities decreased from CNY 776,415,444.06 to CNY 724,223,054.96, representing a decline of about 6.71% [2][3] - The total equity increased from CNY 1,514,108,699.56 to CNY 1,596,522,985.97, indicating a growth of approximately 5.46% [2][3] Revenue and Profitability - The total operating revenue for the first half of 2025 was CNY 957,309,406.16, down from CNY 1,008,128,208.10 in the same period of 2024, marking a decrease of about 5.04% [3][4] - Total operating costs decreased from CNY 897,060,160.66 to CNY 837,453,429.08, a reduction of approximately 6.65% [3][4] - The net profit for the first half of 2025 was CNY 100,293,909.16, compared to CNY 86,792,633.13 in the previous year, reflecting an increase of about 15.25% [4][5] Cash Flow - The net cash flow from operating activities was CNY 23,107,715.29, a decrease from CNY 51,569,414.20 in the previous year [6][7] - Cash and cash equivalents at the end of the period were CNY 562,916,068.85, down from CNY 586,430,669.66 at the beginning of the period [6][7] Expenses - Selling expenses decreased significantly from CNY 121,398,899.05 to CNY 66,029,184.50, a reduction of approximately 45.49% [4][5] - Research and development expenses increased from CNY 9,226,381.24 to CNY 11,833,550.53, reflecting a growth of about 28.38% [4][5] Earnings Per Share - Basic and diluted earnings per share for the first half of 2025 were CNY 0.1683, up from CNY 0.1457 in the same period of 2024, indicating an increase of approximately 15.93% [4][5]
北大医药: 2025年半年度财务报告